Bill > HR1405

This bill directs the Comptroller General (the head of the Government Accountability Office) to conduct a comprehensive study on regulatory barriers affecting pharmaceutical manufacturing in the United States. The study will examine how environmental and other regulations potentially delay or increase costs for pharmaceutical manufacturers when expanding or establishing new facilities, and how these regulations compare to those in other countries. The Comptroller General will engage with stakeholders to identify regulatory challenges, explore potential technological solutions, and assess the impact of these regulations on pharmaceutical supply chain resilience. Specifically, the study will investigate whether current regulations make the U.S. less competitive as a manufacturing location, consider potential actions regulators could take to address barriers (such as expediting reviews and approvals), and identify policies that could support manufacturing innovation. Within one year of the bill's enactment, the Comptroller General must submit a report to Congress that not only identifies and assesses these regulatory barriers but also provides recommendations for streamlining regulations and facilitating technological solutions to enhance domestic pharmaceutical manufacturing capabilities. The bill, named the "Enhancing Domestic Drug Manufacturing Competitiveness Act," aims to strengthen the U.S. pharmaceutical manufacturing sector by understanding and potentially mitigating regulatory obstacles.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/1405/all-info